18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
ConditionPheochromocytoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital of Zhejiang University
About this trial
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility criteria
Qualifiers
Aged 30-80 years old, primary school or above, with a regular caregiver;
Clinically diagnosed patients with pheochromocytoma;
Can provide informed consent, can understand and comply with the study requirements.
Disqualifiers
Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
Patients with mental disorders or primary affective disorders;
Unable to understand and adhere to the study protocol or provide informed consent;
Trial design
Treatments tested in this trial
- 18F-MFBG
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov